Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GEN1053 |
| Synonyms | |
| Therapy Description |
GEN1053 is a hexamer-forming antibody that targets CD27, potentially leading to increased CD27-dependent signaling, expansion of immune cells, and activation of cytotoxic T-lymphocyte (CTL) mediated antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GEN1053 | BNT 313|BNT-313|BNT313|GEN 1053|GEN-1053 | GEN1053 is a hexamer-forming antibody that targets CD27, potentially leading to increased CD27-dependent signaling, expansion of immune cells, and activation of cytotoxic T-lymphocyte (CTL) mediated antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05435339 | Phase Ib/II | GEN1053 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | Terminated | USA | ESP | 0 |